NR4A1 and breast cancer: The HER2+ variant represents 20% of newly diagnosed breast cancer cases and is characterized by a high expression of the protein HER2 and a loss of the hormonal receptors in tumors of greater histological grade [209], but they also can be classified as luminal type [210].